Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) EBIT Margin: 2021-2025

Historic EBIT Margin for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to 29,287.09%.

  • SAB Biotherapeutics' EBIT Margin rose 1479460.00% to 29,287.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 69,102.73%, marking a year-over-year increase of 7271157.00%. This contributed to the annual value of -3,244.87% for FY2024, which is 154432.00% down from last year.
  • SAB Biotherapeutics' EBIT Margin amounted to 29,287.09% in Q3 2025, which was up 93.64% from 15,124.81% recorded in Q2 2025.
  • Over the past 5 years, SAB Biotherapeutics' EBIT Margin peaked at 29,287.09% during Q3 2025, and registered a low of -8,726.26% during Q4 2024.
  • For the 3-year period, SAB Biotherapeutics' EBIT Margin averaged around 4,102.29%, with its median value being -1,205.90% (2024).
  • Per our database at Business Quant, SAB Biotherapeutics' EBIT Margin plummeted by 747,037bps in 2023 and then skyrocketed by 1,900,177bps in 2025.
  • Quarterly analysis of 5 years shows SAB Biotherapeutics' EBIT Margin stood at -66.41% in 2021, then plummeted by 29,733bps to -363.74% in 2022, then slumped by 582,416bps to -6,187.90% in 2023, then slumped by 253,836bps to -8,726.26% in 2024, then spiked by 1,479,460bps to 29,287.09% in 2025.
  • Its EBIT Margin stands at 29,287.09% for Q3 2025, versus 15,124.81% for Q2 2025 and 15,484.95% for Q1 2025.